CN105935374A - Application of Quanmasu in preparation of drugs for treatment of diabetes - Google Patents
Application of Quanmasu in preparation of drugs for treatment of diabetes Download PDFInfo
- Publication number
- CN105935374A CN105935374A CN201610414476.9A CN201610414476A CN105935374A CN 105935374 A CN105935374 A CN 105935374A CN 201610414476 A CN201610414476 A CN 201610414476A CN 105935374 A CN105935374 A CN 105935374A
- Authority
- CN
- China
- Prior art keywords
- industrial hemp
- fructus cannabis
- general anesthesia
- diabetes
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title abstract description 11
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 62
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 61
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 61
- 235000009120 camo Nutrition 0.000 claims abstract description 61
- 235000005607 chanvre indien Nutrition 0.000 claims abstract description 61
- 239000011487 hemp Substances 0.000 claims abstract description 61
- 239000000284 extract Substances 0.000 claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 241000218236 Cannabis Species 0.000 claims abstract 7
- 238000002695 general anesthesia Methods 0.000 claims description 62
- 239000000835 fiber Substances 0.000 claims description 27
- 238000000605 extraction Methods 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 16
- 241000159750 Urtica cannabina Species 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 42
- 239000008280 blood Substances 0.000 abstract description 42
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 34
- 239000008103 glucose Substances 0.000 abstract description 34
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 238000002651 drug therapy Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000010030 glucose lowering effect Effects 0.000 abstract 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 240000004308 marijuana Species 0.000 description 48
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 23
- 235000000346 sugar Nutrition 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 11
- 229950011318 cannabidiol Drugs 0.000 description 11
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 11
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000002218 hypoglycaemic effect Effects 0.000 description 9
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 7
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 7
- 229960004242 dronabinol Drugs 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 238000012109 statistical procedure Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229960001052 streptozocin Drugs 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000011697 diabetes animal model Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010024604 Lipoatrophy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000008882 Tang Maikang Substances 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- -1 glucose carbohydrate Chemical class 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000014058 juice drink Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000009874 shenqi Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of Quanmasu in preparation of drugs for treatment of diabetes. The Quanmasu is prepared by uniform mixing of an industrial hemp fructus cannabis extract and 99.7-0.3 parts by weight of industrial hemp Huomasu. Experiments prove that the Quanmasu can significantly reduce the blood glucose value of animals with diabetes, improve abnormal glucose tolerance, improve abnormal lipid metabolism, also has an inhibitory effect on blood glucose rise in normal animals after oral taking of glucose, and has no obvious influence on the blood glucose of normal animals. Drug therapy clinical observation is carried out on 100 cases of patients with type II diabetes and finds that a Quanmasu active component has a blood glucose lowering effect and the total effective rate reaches 95%. Quanmasu has medication safety and has definite blood glucose lowering efficacy.
Description
Technical field
The invention belongs to industrial hemp and utilize technical field, concretely relating to one with industrial hemp is
The pharmaceutical composition that primary raw material prepares application in preparation treatment diabetes medicine.
Background technology
The plantation of Fructus Cannabis is with a long history, ancient times Fructus Cannabis be mainly used in fabrication and processing rope, fishing net, clothing and
Paper making raw material, and oils and fats, food etc..Development and progress along with society, it has been found that contain in Fructus Cannabis
Having a kind of toxic component (tetrahydrocannabinol) that people can be made to cause unreal addiction, American-European many countries are once considerably long
Forbid cultivating in period Fructus Cannabis.Owing to the economic use value of Fructus Cannabis is high, to the eighties in 20th century, some Europe
Low toxicity Hemp Varieties the plantation that puts it over have been cultivated in the research of continent country.Nineteen ninety, the European Community took the lead in promptly
Revision agricultural policy, has abolished the ban of Fructus Cannabis of forbidding cultivating, has started to recover the production of Fructus Cannabis and research.Subsequently
The states such as the U.S., Canada, Australia relieve Fructus Cannabis plantation ban, the whole world Fructus Cannabis cultivated area and
Fiber production has had and has increased rapidly, and the exploitation of industrial hemp are started by American-European countries again, international city
The demand of ecological Fructus Cannabis is also being increased rapidly by field.According to the economic attribution of Fructus Cannabis, for making full use of it it is
The mankind service, and within 1988, the United Nations's clear stipulaties does not possess extraction toxic component (tetrahydrocannabinol THC)
It is worth or sucks directly as drugs, specializing in the raw material Fructus Cannabis of industrial use, industrial hemp (its growth
Tetrahydrocannabinol content in phase Fructus Cannabis floral leaf is less than 0.3%), legal can carry out implantation in large scale and work
Industryization develops.
Industrial hemp be show unique characteristics, living resources that comparative advantages are prominent.Industrial hemp and conventional toxic
Fructus Cannabis has essential distinction, and industrial hemp is the raw material of industry product of a class Non-toxic, has high warp
Ji value.Successively 25 industrial hemp kinds are selected altogether to countries in the world at the end of 2003, and
And seven states such as the method for European Union, moral, English the most all become industrial hemp and mainly plant manufacturing country, with industrial hemp
Fiber and fiber crops seed and flower thereof, leaf, root, stem are that raw material carries out series of products research and development and industrialization comprehensive exploitation,
Industrial hemp primary process major product jute skin fiber, stalk core fibre, hemp seed oil fat and seed cake protein,
On the basis of medicinal standard extract realizes industrialization production, carry out deep processing and utilization further, derive from
Product out has reached more than 25,000 kinds, contain the clothing of the mankind, food, shelter, row, with each greatly
Series products.The research of industrial hemp industry, develop and production is concentrated mainly on Europe, Canada, the U.S.
Etc. technology developed country.The development of industrial hemp industry, is first nontoxic from selection-breeding or the low industry poisoned
Fructus Cannabis new varieties start, and achieve the plantation of scale and combining of hi-tech industrialization based on this
Close and develop, define one " emerging pollution-free industry group " and the quick growth point of infant industry economy.
Fructus Cannabis is Fructus Cannabis dry mature fruit, is generally used as medicine by Fructus Cannabis ancient times, and dietetic therapy is the most on the books.
Fructus Cannabis is included in " being medicine and food " " medicine-food two-purpose " list by health ministry.
The property of medicine of Fructus Cannabis and pharmacology be: sweet, flat.Return spleen, stomach, large intestine channel.Function cures mainly: moisturize, sliding
Intestinal, treating stranguria, invigorate blood circulation.Control dryness of the intestine constipation, quench one's thirst, pyretic stranguria, migratory arthralgia, dysentery.Menoxenia, scabies,
Tinea leprosy.Those benefits in detail is had to record in medical book, such as " herbal classic ": " invigorating the spleen and replenishing QI.”；Tang Materia Medica: " main
Five kinds of over strain.”；" Handbook of Prescriptions for Emergencies ": " control extreme thirst, day eclipse number bucket, hot urination person: pockmarks one liter, three liters of water,
Boiling three, four boilings, extracting juice drinks it.”；" Japan hanako materia medica ": " qi-restoratives labor, long muscle, stimulating milk secretion, only disappear
Yearningly, expedite the emergence of.Control perverse and unreasonable manner to produce.”；Supplement to the Herbal: " therapeutic method to keep the adverse QI flowing downwards, diuresis, go migratory arthralgia skin stupid, fries order
Perfume (or spice) is smashed to pieces, urine leaching juice clothes；Married woman's footling presentation gulps down two or seven pieces.”；" Treatise on Dietetic Therapy ": " extracting juice is cooked congee,
Go the five internal organs wind, lung moistening.Control that joint is obstructed, deal with, promoting blood circulation.”.
The equal hyoscine of floral leaf of Fructus Cannabis.The property of medicine of Folium Cannabis and pharmacology be: pungent；Poisonous.Return lung；Bladder；
Large intestine channel.Function cures mainly: pain relieving, and Dingchuan drives ascarid.Cure mainly asthma, fall and flutter pain, ascariasis.Fiber crops
The property of medicine and the pharmacology of flower be: bitter；Pungent；Warm in nature；Poisonous.Function cures mainly: dispel the wind；Invigorate blood circulation；Hair growth promoting.
Main air disease numb limbs and tense tendons；Pruritus all over；Women's amenorrhea.
Diabetes is the name of disease of Chinese medicine, refer to polydipsia, polyuria, polyphagia and become thin, tired,
Urinate the sweet symptomes complice for principal character.If doing laboratory examination, it is mainly characterized by hyperglycemia and glucose in urine.Main
Will be at lung, stomach, kidney, basic pathogenesis is cloudy body fluid deficiency consumption, scorching inclined Sheng.Quenching one's thirst with the passing of time, the state of an illness is out of control,
Then deficiency of YIN affecting YANG, the bright blood stasis due to loss of body fluid of heat, and cause impairment of both QI and YIN, deficiency in both YIN and YANG, channels stasis blocking, passages through which vital energy circulates loses
Supporting, QI and blood is inverse disorderly, internal organs impaired organ and furuncle, carbuncle, dizziness, the thoracic obstruction, deafness, blindness, limb occur
The double disease such as body fiber crops pain, lower limb gangrene, renal failure edema, apoplectic coma.
Diabetes can not refer in particular to diabetes.But the modern treatment of diabetes be have employed current diabetes more
Medicine, including orally-taken blood sugar reducing medicine and insulin.
Orally-taken blood sugar reducing medicine includes: (1) sulfonylurea drugs；(2) biguanides；(3) prandial glucose
Regulator；(4) alpha-glucosidase inhibitor；(5) aldose reductase inhibitor；(6) thiazolidinedione
Para-insulin sensitizer；(7) other drug.
But use hypoglycemic medicine and insulin to there is serious untoward reaction, such as: the untoward reaction of insulin
Have: (1) anaphylaxis, use the patient of insulin to there will be urticaria and nervus vasculairs in injection site
Property edema；(2) hypoglycemic reaction；(3) insulin resistant；(4) injection site be lipoatrophy or
Hypertrophy；(5) refraction of eye imbalance.
The untoward reaction of sulfonylurea drugs: accidental hypoglycemia, can have diarrhoea, Nausea and vomiting, headache,
Stomachache or uncomfortable, erythra is more rare, and rare and serious has jaundice, liver function injury, granulocytopenia
(show as pharyngalgia, generate heat, infect), thrombocytopenia (showing as hemorrhage, purpura) etc..
The untoward reaction of biguanides is most commonly that: gastrointestinal reaction, shows as inappetence, evil
The heart, vomit, suffer from diarrhoea, have a stomachache, metallic taste etc. in mouth.Sometimes patient have weak, tired, lose weight,
Dizziness and erythra etc..
The untoward reaction of Study of Thiazolidinedione derivatives as Insulin Sensitizer includes: (1) anemia；(2) cardiovascular system
Reaction；(3) neuropsychiatric reaction；(4) hypoglycemic reaction；(5) gastrointestinal reaction etc..
The Chinese patent medicine that treatment diabetes is conventional at present mainly has following several: (1) diabetes pill；(2) JIANGTANGSHU；
(3) YUQUAN WAN；(4) blood sugar lowering first sheet；(5) Ganluxiaoke capsules；(6) LIUWEI DIHUANG WAN, MAIWEIDIHUANGWAN；
(7) SHIHUYEGUANG WAN；(8) Radix Rehmanniae Pilulae for Improving Eyesight；(9) SHENQI JIANGTANG sheet；(10) Kelening capsule；(11)
Xiao Ke Lin sheet；(12) JINQI JIANGTANG PIAN；(13) TANGMAIKANG KELI；(14) ten eight taste Fructus Chebulae's diuresis balls.To the greatest extent
Pipe is such, but the curative effect of these Chinese medicine preparation is the most unsatisfactory.
Cannabidiol (CBD) is that a kind of nontoxic of extraction from Fructus Cannabis floral leaf can be used for medicine, cosmetic
Product, the aldehydes matter of a kind of high added value of health food.At present, Israel, the U.S., Britain etc. are sent out
Reach country done raw material with it and developed multiple special effect medicine and cosmetics.CBD is the non-one-tenth in Fructus Cannabis
Addiction composition, can hinder THC to affect nerve system of human body, and have spasmolytic, antirheumatic joint
The pharmacologically actives such as inflammation, anxiety.Also there is the report in terms for the treatment of diabetes, but be used alone Fructus Cannabis two
The therapeutic effect of phenol (CBD) is unsatisfactory.
Therefore, the medicine of the treatment diabetes that people are less to better efficacy, side effect still suffers from strongly needing
Ask.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition prepared with industrial hemp for primary raw material
The application in pharmacy of the general anesthesia element.
It practice, the present invention relates to the application in the medicine of preparation treatment diabetes of the general anesthesia element；Described
General anesthesia element is by 0.3 part～the industrial hemp Fructus Cannabis extract of 99.7 weight portions and 99.7 parts～0.3 weight
The industrial hemp Urtica cannabina L. element mixing of amount part is made.
The raw material composition of described general anesthesia element is preferably industrial hemp Fructus Cannabis extract 40 parts and industry is big
Fiber crops Urtica cannabina L. element 60 parts.
Wherein, described industrial hemp Fructus Cannabis extract is prepared by the following method and forms:
(1) ripe industrial hemp Fructus Cannabis is taken, drying, remove impurity, standby after pulverizing；
(2) under the conditions of 20～85 DEG C, extract pulverizing Fructus Cannabis material with ethanol, concentration of alcohol
Being 95%～100% (V/V), solid-liquid ratio is 1:5～1:20；
(3) leach lixiviating solution, after concentrating under reduced pressure, be industrial hemp Fructus Cannabis extract.
When industrial hemp Fructus Cannabis being extracted with ethanol, following various ways can be used to carry out: as
Extract under room temperature, every batch materials extraction 2 times, each 7～10 days；Under the conditions of 60～85 DEG C, heating
Extract 2 times, each 1～3 hour；Ultrasonic assistant extracts, ultrasonic frequency 30～60kHz, merit
Rate 100～1000W, extraction time 30～60min, extraction temperature 25～50 DEG C；Also microwave can be used
Other prior art such as assisted extraction.
Described industrial hemp Urtica cannabina L. element is prepared by the following method and forms:
(1) flower of industrial hemp, leaf, fiber crops bran or the mixture of three, drying, remove impurity, powder are taken
It is broken to 10～60 mesh；
(2) supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is put into supercritical
In carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～90min, extraction
Pressure 25～35Mpa, carbon dioxide flow 40kg/h, extract is collected in separating still outlet；
(3) the extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume, eluting
Number of times is 1～3 time；
(4) eluent is collected, concentrating under reduced pressure, vacuum drying, i.e. obtain industrial hemp Urtica cannabina L. element after pulverizing.
The flower of described industrial hemp, leaf, the optimum ratio of fiber crops bran three's mixture are 1:3:2.
Common Folium Cannabis, Flos Cannabis be respectively provided with toxicity (containing tetrahydrocannabinol THC marijuana hemp to the most unreal
Material).For getting rid of the toxicity of crude drug, present invention preferably employs the industrial hemp kind of Yunnan growth
Flower, leaf, fiber crops bran and the Fructus Cannabis of " cloud fiber crops No. 1 " are as raw material.By China's relevant legal documents rule
Fixed, " cloud fiber crops No. 1 " can only be planted within the border in Yunnan, and its flower, leaf, numb bran can only be in border, Yunnan
Interior processing.
The pharmaceutical composition general anesthesia element of the present invention can make different pharmaceutical preparation, further including being administered orally
Agent and injection, wherein oral agents includes capsule, oral liquid, tablet, drop pill, granule etc., injection
Including injection dosage form and freeze-dried powder injection type etc..The available auxiliary type when preparing oral formulations
Agent can be the conventional filler such as starch, dextrin or cyclodextrin, sucrose, stearate.Lyophilized injectable powder
Can be prepared by methods such as aseptic spray drying, low-temperature vacuum drying, lyophilizations.After each preparation
Phase preparation technology and equipment all belong to the routine techniques of pharmaceutical field, and this is not construed as limiting by the present invention, therefore at this
Not describe in detail.
The pharmaceutical composition general anesthesia element of the present invention has the effect of clear and definite treatment diabetes.For ease of
Understanding general anesthesia element medical value in terms for the treatment of diabetes, inventor makes the general anesthesia prepared in aforementioned manners
Element and corresponding pharmaceutical dosage form, have employed different animal models, and complete observation general anesthesia element is to diabetes
The impact of blood glucose, carbohydrate tolerance and blood lipid metabolism under state, under normal physiological condition.Experiment proves complete
Fiber crops have the effect of clear and definite treatment diabetes, can obviously reduce the blood glucose value of diabetes animal, improve sugar
The exception of tolerance, improves abnormalities of sugar/lipid metabolism；Blood glucose after intact animal's oral glucose is raised and also has
Having inhibitory action, zoopery curative effect is certainly.Normal animal blood glucose is had no significant effect by general anesthesia element, explanation
It is less that it induces hypoglycemic probability, and medication is comparatively safe.100 example type ii diabetes patients are entered
Row drug therapy clinical is observed, and general anesthesia element active component has hypoglycemic activity, and total effective rate reaches
95%.Therefore general anesthesia element of the present invention has clear and definite treatment diabetes effect, effect is better than Fructus Cannabis two
Phenol.
Detailed description of the invention
Below by embodiment, the present invention is described in further detail, but embodiment is not to this
The restriction of bright technical scheme.
Embodiment 1
Use flower, leaf, fiber crops bran and the Urtica cannabina L. of the industrial hemp kind " cloud fiber crops No. 1 " of Yunnan growth
Core is as raw material.Take maturation industrial hemp Fructus Cannabis, drying, remove impurity, standby after pulverizing；Use second
Alcohol to pulverize Fructus Cannabis material extract (under the conditions of 60～85 DEG C, heating extraction 2 times, each 1～
3 hours), concentration of alcohol is 95%～100% (V/V), and solid-liquid ratio is 1:5～1:20；Leach lixiviating solution,
Industrial hemp Fructus Cannabis extract it is after concentrating under reduced pressure.
Take the flower of industrial hemp, leaf, fiber crops bran 1:3:2 mass ratio mixture, drying, remove impurity,
It is crushed to 10～60 mesh；Supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is thrown
Enter in supercritical carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～
90min, extracting pressure 25～35Mpa, carbon dioxide flow 40kg/h, extraction is collected in separating still outlet
Thing；The extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume, washing steps
It it is 1～3 time；Collect eluent, concentrating under reduced pressure, vacuum drying, after pulverizing, obtain industrial hemp Urtica cannabina L.
Element.
Take industrial hemp Fructus Cannabis extract 40 parts, industrial hemp Urtica cannabina L. element 60 parts, mixing, obtain required
General anesthesia element B.
Embodiment 2
Repeat embodiment 1, have following difference: when industrial hemp Fructus Cannabis being extracted with ethanol,
Extract under room temperature, every batch materials extraction 2 times, each 7～10 days.Take the flower of industrial hemp, leaf, fiber crops
The mixture of bran 1:1:1 mass ratio is as the extraction raw material of industrial hemp Urtica cannabina L. element.
Take industrial hemp Fructus Cannabis extract 0.3 part, industrial hemp Urtica cannabina L. element 99.7 parts, mixing, obtain
Required general anesthesia element A.
Embodiment 3
Repeat embodiment 1, have following difference: when industrial hemp Fructus Cannabis being extracted with ethanol,
Employing ultrasonic assistant extracts, and ultrasonic frequency 30～60kHz, power 100～1000W, during extraction
Between 30～60min, extraction temperature 25～50 DEG C.Take the flower of industrial hemp, leaf, fiber crops bran 3:2:1 matter
The mixture of amount ratio is as the extraction raw material of industrial hemp Urtica cannabina L. element.
Take industrial hemp Fructus Cannabis extract 99.7 parts, industrial hemp Urtica cannabina L. element 0.3 part, mixing, obtain
Required general anesthesia element C.
Embodiment 4
Example 1 gained medicine 100 grams (crosses 80 mesh sieves), adds 60 grams of microcrystalline Cellulose, crosses 80
Mesh sieve three times, mix homogeneously, spray into 95% ethanol solution, soft material processed, cross 40 mesh sieves and pelletize, 60 DEG C
It is dried half an hour, is sub-packed in 3# capsule, aluminium plastic composite packaging, prepare general anesthesia cellulose capsule agent.
Embodiment 5
Example 2 gained medicine, admixture doses 5～the dried starch of 20% and 1～the stearic acid of 5%
Magnesium etc., blended, pelletize, be dried, tabletting, prepare general anesthesia element tablet.
Embodiment 6
The adjuvants such as Example 3 gained medicine, adds sucrose water and the preservative of convention amount, stabilizer.
Filtration, sterilizing, be distributed in 10mL bottle, make general anesthesia element oral liquid.
Embodiment 7
Example 1 gained medicine, adds water for injection and dissolves, add 2.0 ‰ activated carbons, stir,
Filter, continue, with 0.45 μm, 0.22 μm microporous filter membrane classified filtering, to supplement water for injection, subpackage
In cillin bottle, lyophilization, recharge high-purity nitrogen, jump a queue, gland, packaging, prepare general anesthesia element
Injection.
The Application Example 1 general anesthesia element therapeutical effect to model induced by alloxan mice hyperglycemia
For observing the impact on the hyperglycemia mouse blood sugar value of model induced by alloxan of the general anesthesia element, choose body weight
18～22g health Male Kunming strain mice, lumbar injection alloxan (200mg/kg) causes chemical sugar
The sick mouse model of urine, respectively with general anesthesia element A, B, No. C and cannabidiol with the dosage gavage of 20mg/kg,
Every day 1 time, continuous 21 days, took blood, with fasting blood sugar in the 7th day, the 14th day, the 21st day
Blood sugar reducing function for index study general anesthesia element.Result see table:
Table 1 general anesthesia element is administered latter 7 days, 14 days, the fasting blood sugar of 21 days each treated animals
Note: compare with Normal group,△△△P ＜ 0.001；Compare with model control group*P ＜ 0.05,**P ＜ 0.01,***P ＜ 0.001；With
Cannabidiol group compares#P ＜ 0.05,##P ＜ 0.01.
Above-mentioned test result indicate that: 7 days, 14 days and 21 days after medicine, model comparison sample and normal control sample
Having the significance difference opposite sex (P ＜ 0.001), prompting models successfully.7 days, 14 days and 21 days after medicine, A,
B, C general anesthesia all obvious than blood glucose value with model control group reduction of element, has significantly through statistical procedures difference
Property (P ＜ 0.05～0.001)；Compare with cannabidiol group, after medicine 7 days, 14 days and 21 days No. B complete
Fiber crops element, after A general anesthesia element after 14 and 21 days, medicine, 21 days C general anesthesia element hypoglycemic effects are equal after medicine
It is better than cannabidiol group, has significance (P ＜ 0.05～0.01) through statistical procedures difference.Conclusion: complete
Fiber crops element has obvious blood sugar reducing function to model induced by alloxan hyperglycemia mice, and hypoglycemic effect is better than Fructus Cannabis two
Phenol.
The Application Example 2 general anesthesia element therapeutical effect to streptozotocin induction mice hyperglycemia
Observe the impact on the hyperglycemia mouse blood sugar value of streptozotocin induction of the general anesthesia element.Select 10 at random
Mice is Normal group, and tail vein injection citric acid solution 0.1ml/10g, and other mice is all pressed
According to the streptozotocin solution of same volume tail vein injection 2%, survey fasting blood sugar after 72 hours, select
Blood glucose value higher than the mice of 11.1mmol/L, points 5 groups, i.e. model group, cannabidiol group, general anesthesia element A,
B, C group (20mg/kg), by 0.2ml/10g gastric infusion, respectively be administered the 7th day, the 14th day,
Take blood after 21st day socket of the eye, measure blood glucose value.Result see table:
The fasting blood sugar impact on streptozotocin induction hyperglycemia mice of the table 2 general anesthesia element
Note: compare with Normal group,△△△P ＜ 0.001；Compare with model control group*P ＜ 0.05,**P ＜ 0.01,***P ＜ 0.001；With
Cannabidiol group compares#P ＜ 0.05,##P ＜ 0.01.
Above-mentioned test result indicate that: 7 days, 14 days and 21 days after medicine, model comparison sample and normal control sample
Having the significance difference opposite sex (P ＜ 0.001), prompting models successfully.7 days, 14 days and 21 days after medicine, A,
B, C general anesthesia all obvious than blood glucose value with model control group reduction of element, has significantly through statistical procedures difference
Property (P ＜ 0.01～0.001)；Compare with cannabidiol group, after medicine 7 days, 14 days and 21 days No. B complete
Fiber crops element, after A general anesthesia element after 14 and 21 days, medicine, 21 days C general anesthesia element hypoglycemic effects are equal after medicine
It is better than cannabidiol group, has significance (P ＜ 0.05～0.01) through statistical procedures difference.Conclusion: complete
Fiber crops element has obvious blood sugar reducing function to streptozotocin induction mice hyperglycemia, and hypoglycemic effect is better than Fructus Cannabis two
Phenol.
The Application Example 3 general anesthesia element therapeutical effect to type ii diabetes mice
Observe the general anesthesia element shadow to non-insulin-dependent diabetes mellitus (type ii diabetes) mice glucose-lipid metabolism
Ring.Build type ii diabetes animal model, randomly select 10 mices as normal control, give general
Logical feedstuff, remaining mouse tail vein fast injection STZ (30mg/kg), it is aided with high-calorie feed and feeds, from
By drinking water, after 5 weeks, after socket of the eye, blood sampling carries out glucose tolerance test, selects fasting glucose more than 11.1mmol/l
And impaired glucose tolerance mice is as type ii diabetes animal model, and it is divided into model control group, Fructus Cannabis two
Phenol group, general anesthesia element A, B, C group, gastric infusion, every day 1 time, continuous 6 weeks, set up normal simultaneously
Matched group.In being administered 6 weeks laggard row fasting glucose, fasting insulin content, carbohydrate tolerance, the total gallbladders of serum
Sterin (CHO), triglyceride (TG), high (HDL), the detection of low density lipoprotein, LDL (LDL), calculate sugar
Area and insulin sensitivity index under tolerance curve, and liver of weighing, kidney, calculate organ coefficient.Result is shown in
Following table:
6 weeks body weight and the impact of carbohydrate tolerance after table 3 general anesthesia element raticide little on type ii diabetes
Note: compare with Normal group,△△△P ＜ 0.001；Compare with model control group,*P ＜ 0.05,**P ＜ 0.01***P ＜ 0.001；
Compare with cannabidiol group#P ＜ 0.05,##P ＜ 0.01,###P ＜ 0.001.
6 weeks fasting blood sugars after table 4 general anesthesia element raticide little on type ii diabetes, fasting insulin content and insulin sensitivity index/impact
Note: compare with model control group,*P ＜ 0.05,**P ＜ 0.01,***P ＜ 0.001；Compare with Normal group,△P ＜ 0.05,△△△
P ＜ 0.001；Compare with cannabidiol group#P ＜ 0.05,##P ＜ 0.01.
Change of serum C HO, the impact of TG content in 6 weeks after table 5 general anesthesia element raticide little on type ii diabetes
Note: compare with Normal group,△△△P ＜ 0.001；Compare with model control group,*P ＜ 0.05**P ＜ 0.01；With cannabidiol group
Relatively#P ＜ 0.05.
Serum LDL, the impact of HDL content in 6 weeks after table 6 general anesthesia element raticide little on type ii diabetes
Note: compare with Normal group,△P ＜ 0.05；Compare with model control group,*P ＜ 0.05,**P ＜ 0.01.
Liver, the impact of kidney coefficient in 6 weeks after table 7 general anesthesia element raticide little on type ii diabetes
Note: compare with Normal group,△P ＜ 0.05；Compare with model control group,*P ＜ 0.05；Compare with cannabidiol group#P ＜ 0.05.
Above-mentioned test result indicate that: after administration the 6th week, under the glucose tolerance curve of general anesthesia element A, B, C group
Area, change of serum C HO, TG, LDL value are significantly lower than model control group, HDL value, insulin sensitivity index
Apparently higher than model control group, liver coefficient substantially reduces, and Kidney coefficients is without significant change.With Fructus Cannabis two
Phenol group compares, area under the glucose tolerance curve of general anesthesia element A, B, C group, general anesthesia element B group change of serum C HO,
Liver coefficient is significantly lower than cannabidiol group, and general anesthesia element B group insulin sensitivity index is apparently higher than Fructus Cannabis two
Phenol group, has significance through statistical procedures difference.Conclusion: type ii diabetes mice is had by general anesthesia element
Significantly therapeutical effect, therapeutic effect is better than cannabidiol.
Application Example 4 general anesthesia element gastric infusion is on normal mouse blood sugar value and the impact of carbohydrate tolerance
Observe general anesthesia element gastric infusion to normal mouse blood sugar value and the impact of glucose tolerance.60 little
Mus, is randomly divided into 5 groups: blank group, cannabidiol group, general anesthesia element A, B, C group, fills continuously
Stomach was administered after 7 days, with the blood glucose value of different time points as observation index, used steady prompt basic type blood glucose meter
And OneTouch reagent paper measures oral glucose tolerance and is administered the blood glucose value after 1h, between group, compare employing
T checks, and drugs is on normal mouse blood sugar value and the impact of glucose tolerance.Result see table:
Table 8 general anesthesia element is administered the impact of blood glucose value after 1h to normal mouse
The impact on normal Mouse oral glucose carbohydrate tolerance of the table 9 general anesthesia element
Note: compare with blank group, * * * P ＜ 0.001；Compare with cannabidiol group#P ＜ 0.05.
Above-mentioned test result indicate that: each administration group compares with normal group, after administration, 1h blood glucose value changes not
Substantially, through statistical procedures, difference does not has significance.Cannabidiol group compares with normal group, carbohydrate tolerance
Area under curve value reduces substantially, and through statistical procedures, difference has significance (P ＜ 0.001)；Entirely
Fiber crops element A, B, C group compares with normal group, and under glucose tolerance curve, area value all reduces substantially, through statistics
Processing, difference has significance (P ＜ 0.001), and general anesthesia element A, B group compares with cannabidiol group, resistance to
Under discharge curve, area value difference has significance (P ＜ 0.05).Conclusion: the general anesthesia element blood to normal mouse
Sugar acts on without obvious reduction；The blood glucose caused after oral disposition glucose raises obvious reduction effect, effect
Fruit is better than cannabidiol.
The clinical observation of Application Example 5 general anesthesia extract for treating diabetes
1, experimental subject: the type ii diabetes patient made a definite diagnosis by the provisional diagnostic criteria of WHO diabetes, altogether
100 examples.The maleest 50 examples, female 50 example；The course of disease is person 20 example within 1 year, 1-5 person 50 example,
More than 5 years person 30 examples；40 years old 18 example of age ＜, 40-60 year 60 examples, more than 60 22 examples, averagely
52 years old age.
2, Therapeutic Method: treatment group takes capsule (the B general anesthesia element using B general anesthesia element to make
100 grams, make 1000), three times a day, each 6, it was 1 course for the treatment of with one month, serve on
1-3 the course for the treatment of.
3, efficacy assessment standard: clinical remission: fasting glucose ＜ 6.1mmol/L, post-prandial glycemia ＜
8.3mmol/L, transference cure, body weight develops to reference direction；It is effective: fasting glucose ＜ 7.2mmol/L,
Post-prandial glycemia ＜ 10.8mmol/L, symptom substantially alleviates, and body weight develops to reference direction；Effective: on an empty stomach
Blood glucose ＜ 8.3mmol/L, post-prandial glycemia ＜ 11.1mmol/L, symptom has alleviated, and body weight is to standard side
To development；Invalid: each index does not reaches above-mentioned requirements.
4, experimental result is summed up:
| Number of cases | Clinical remission | Effective | Effectively | Invalid | Effective percentage |
| 100 | 36 | 48 | 11 | 5 | 95% |
5, experiment brief summary: the general anesthesia element that the present invention provides has hypoglycemic activity, and total effective rate reaches
95%.
Claims (6)
1. general anesthesia element application in the medicine of preparation treatment diabetes；Described general anesthesia element by 0.3 part～
The industrial hemp Fructus Cannabis extract of 99.7 weight portions and 99.7 parts～the industrial hemp fire of 0.3 weight portion
Fiber crops element mixing is made.
Application the most according to claim 1, it is characterised in that: the raw material group of described general anesthesia element
Become to be preferably industrial hemp Fructus Cannabis extract 40 parts and industrial hemp Urtica cannabina L. element 60 parts.
Application the most according to claim 1, it is characterised in that: described industrial hemp Fructus Cannabis
Extract is prepared by the following method and forms:
(1) ripe industrial hemp Fructus Cannabis is taken, drying, remove impurity, standby after pulverizing；
(2) under the conditions of 20～85 DEG C, extract pulverizing Fructus Cannabis material with ethanol, concentration of alcohol
Being 95%～100% (V/V), solid-liquid ratio is 1:5～1:20；
(3) leach lixiviating solution, after concentrating under reduced pressure, be industrial hemp Fructus Cannabis extract.
Application the most according to claim 1, it is characterised in that: described industrial hemp Urtica cannabina L. element
It is prepared by the following method and forms:
(1) flower of industrial hemp, leaf, fiber crops bran or the mixture of three, drying, remove impurity, powder are taken
It is broken to 10～60 mesh；
(2) supercritical carbon dioxide extraction: the above-mentioned industrial hemp raw material crushed is put into supercritical
In carbon dioxide extraction apparatus, control extraction temperature 40～50 DEG C, extraction time 30～90min, extraction
Pressure 25～35Mpa, carbon dioxide flow 40kg/h, extract is collected in separating still outlet；
(3) the extract ethanol elution of 95%～100% (V/V) of 0.2～10 times of volume, eluting
Number of times is 1～3 time；
(4) eluent is collected, concentrating under reduced pressure, vacuum drying, i.e. obtain industrial hemp Urtica cannabina L. element after pulverizing.
Application the most according to claim 4, it is characterised in that: the flower of described industrial hemp,
Leaf, the optimum ratio of fiber crops bran three's mixture are 1:3:2.
Application the most according to claim 1, it is characterised in that: the kind of described industrial hemp
It is preferably " cloud fiber crops No. 1 ".
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610414476.9A CN105935374A (en) | 2016-06-14 | 2016-06-14 | Application of Quanmasu in preparation of drugs for treatment of diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610414476.9A CN105935374A (en) | 2016-06-14 | 2016-06-14 | Application of Quanmasu in preparation of drugs for treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105935374A true CN105935374A (en) | 2016-09-14 |
Family
ID=57151802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610414476.9A Pending CN105935374A (en) | 2016-06-14 | 2016-06-14 | Application of Quanmasu in preparation of drugs for treatment of diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105935374A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| CN114869868A (en) * | 2022-04-09 | 2022-08-09 | 深圳大学 | Application of cannabidiol in preparation of medicine for treating tauopathy and diabetes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105505565A (en) * | 2015-12-28 | 2016-04-20 | 贵州航天乌江机电设备有限责任公司 | Method for extracting industrial hemp oil rich in cannabidiol |
-
2016
- 2016-06-14 CN CN201610414476.9A patent/CN105935374A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105505565A (en) * | 2015-12-28 | 2016-04-20 | 贵州航天乌江机电设备有限责任公司 | Method for extracting industrial hemp oil rich in cannabidiol |
Non-Patent Citations (1)
| Title |
|---|
| 赵翾等: "响应面法优化火麻仁黄酮提取工艺", 《食品科学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11084770B2 (en) | 2016-12-07 | 2021-08-10 | Treehouse Biotech, Inc. | Cannabis extracts |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| CN114869868A (en) * | 2022-04-09 | 2022-08-09 | 深圳大学 | Application of cannabidiol in preparation of medicine for treating tauopathy and diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048933B (en) | Chinese medicinal composition for treating infantile diarrhea and preparation method thereof | |
| CN103719498B (en) | A kind of Siberian solomonseal rhizome health-care tea improving immunity and preparation method thereof | |
| CN105943615A (en) | Application of whole hemp extract in preparation of pancreatic cancer treating drug | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN105943618A (en) | Drug for treating depression | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN105935374A (en) | Application of Quanmasu in preparation of drugs for treatment of diabetes | |
| CN105943613A (en) | Application of whole hemp extract in preparation of drug for preventing and controlling cardiovascular and cerebrovascular diseases | |
| CN102631595A (en) | Medicament for treating II-type diabetes mellitus and preparation method thereof | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN104286864B (en) | A kind of semen astragali complanati oral liquid improving immunity and preparation method thereof | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN107412713A (en) | Treat Chinese patent drug, dietetic food and the preparation method of autoimmune and immune related diseases | |
| CN106074707A (en) | The application in pancreatitic medicine is treated in preparation of the general anesthesia element | |
| CN105963359A (en) | Application of all-cannabinoid in preparation of drugs for treating depression | |
| CN105943619A (en) | Application of whole hemp extract in preparation of drug for preventing and treating Alzheimer's disease | |
| CN105963355A (en) | Medicine for preventing and treating senile dementia | |
| CN105998194A (en) | Antithrombotic medicine | |
| CN106074710A (en) | A kind of medicine treating epilepsy | |
| CN100493578C (en) | A traditional Chinese medicine composition for treating emaciation and weak constitution and preparation method thereof | |
| CN105935375A (en) | Application of Quanmasu in preparation of anti-aging drugs | |
| CN105998191A (en) | Application of general anesthetic to preparation of drugs for treating gout | |
| CN105920104A (en) | Age-defying drug | |
| CN106074708A (en) | The application in preparation treatment AED of the general anesthesia element |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Chenfeng Inventor after: Hu Chengyue Inventor before: Chen Tianrui Inventor before: Hu Chengyue |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160914 |